Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Aug 1.

Published in final edited form as: Radiother Oncol. 2020 Apr 27;149:64–69. doi: 10.1016/j.radonc.2020.04.038

Fig 2 — — Disease-free survival by prostate-specific antigen (PSA) category at 4 years for the 3 validation cohorts. (A) Favorable risk (Australia: 75% favourable risk and 25% intermediate risk). (B) Intermediate risk (MD Anderson). (c) High risk (Ascende RT: 70% high risk and 30% upper tier intermediate risk).

Fig 2 — — Disease-free survival by prostate-specific antigen (PSA) category at 4 years for the 3 validation cohorts. (A) Favorable risk (Australia: 75% favourable risk and 25% intermediate risk). (B) Intermediate risk (MD Anderson). (c) High risk (Ascende RT: 70% high risk and 30% upper tier intermediate risk).